

Review

The role of small-colony variants in failure to diagnose and treat biofilm infections in orthopedics

Daniëlle Neut^{1,2}, Henny C van der Mei¹, Sjoerd K Bulstra², and Henk J Busscher¹

Departments of ¹Biomedical Engineering and ²Orthopaedic Surgery, University Medical Center Groningen, and University of Groningen, Groningen, the Netherlands

Correspondence DN: d.neut@med.umcg.nl

Submitted 06-07-19. Accepted 06-10-30

ABSTRACT Biomaterial-related infection of joint replacements is the second most common cause of implant failure, with serious consequences. Chronically infected replacements cannot be treated without removal of the implant, as the biofilm mode of growth protects the bacteria against antibiotics. This review discusses biofilm formation on joint replacements and the important clinical phenomenon of small-colony variants (SCVs). These slow-growing phenotypic variants often remain undetected or are misdiagnosed using hospital microbiological analyses due to their unusual morphological appearance and biochemical reactions. In addition, SCVs make the infection difficult to eradicate. They often lead to recurrence since they respond poorly to standard antibiotic treatment and can sometimes survive intracellularly.

In the USA alone, 250,000 hip replacements and 400,000 knee replacements are done every year (Kurtz et al. 2005). These numbers are expected to double before the year 2030 because of the general increase in average age globally and growing demands for a higher quality of life.

As with all other biomaterials in humans, the use of joint replacements bears the risk of attracting infectious microorganisms. There are several theories on how infections of joint prostheses develop.

Most studies on the interaction of the prosthesis with infecting organisms have shown that bacteria readily attach to devices during implantation (Lidwell et al. 1983). The main sources of contamination are the patient's skin and airborne particles from theater personnel (Pittet and Ducloux 1994). The adhesion of bacteria itself is a complicated process. All biomaterials undergo changes at the surface after implantation. The earliest and probably clinically most important step is the "race for the surface", a contest between tissue cell integration and bacterial adhesion to that same surface (Gristina 1987). On contact, body fluids immediately coat all surfaces with a layer of host material, mainly plasma proteins and platelets. These host proteins promote attachment of bacteria onto the implant by specific receptors and by non-specific mechanisms that may depend on their chemical composition, their hydrophobicity, and the charge of the implant surface (Bos et al. 1999). After their adhesion, the bacteria encase themselves in a hydrated matrix of polysaccharides and proteins (Costerton et al. 1999) to form a slimy layer known as a biofilm (Figure 1).

Bacteria within this protective biofilm can remain "dormant" on the surface of a prosthesis for a long time; however, when the environmental circumstances change—such as reduced host immune function—biofilm bacteria can cause a clinical




Figure 1. Confocal laser scanning microscope overlay image of a 4-day-old *Staphylococcus aureus* biofilm on polyethylene. The sample was stained with a live/dead stain (green/red) and with Calcofluor white (blue) for slime staining. The bar represents 10 μ m.

infection. Generally speaking, biofilm infections will not clear until the implant has been removed and the patient must then be given antibiotic therapy. This treatment can prolong the patient's stay in hospital by several weeks, and additional surgery may be required. Infection is thus a devastating complication from the point of view of both the patient and society, as it is associated with a substantial increase in morbidity and adds significant costs to the healthcare system.

The infection rate from joint replacements has dropped dramatically since the procedure was first performed in the late 1960s, but even so about 1% of all patients develop such an infection (Josefsson and Kolmert 1993, Philips and Crane 2006). This percentage may seem small, but since these joint replacement operations are so common, it is a complication that affects a significant number of patients. Moreover, biofilm infections can cause severe problems, ranging from disfunctioning of the implanted device to lethal sepsis. Furthermore, treatment of biofilm infections is complicated, as biofilms offer enhanced protection for the infecting organisms against the natural host defenses and antibiotic therapy (Gristina and Costerton 1985). Bacteria in a biofilm are able to resist higher antibiotic concentrations than planktonic bacteria. In general, bacteria in a biofilm are 10–1,000 times more resistant to antibiotics than their planktonic

counterparts (Widmer 2001, Mah et al. 2003). Also, some bacteria (such as *Staphylococcus aureus*) form small-colony variants, characterized by reduced growth rate, resistance to aminoglycosides, and possible intracellular persistence (Proctor and Peters 1998).

In this review we first summarize current knowledge regarding the formation of an infectious biofilm on orthopedic implants, and the mechanisms used by infectious organisms to cause a deep and chronic infection. We pay special attention to the role of strains resulting from a modification of bacterial phenotype, so-called small-colony variants (SCVs), in biofilms. Finally we review the failures in diagnosis and treatment in orthopedic surgery caused by SCVs, including possible clinical consequences.

Small-colony variants (SCVs)

The pathogenesis of many orthopedic infections is related to the presence of microorganisms in biofilms. Bacteria that attach to a surface and grow as a biofilm are protected from the killing action of antibiotics. The protective mechanisms at work in biofilms appear to be distinct from those that are responsible for conventional antibiotic resistance (Gracia et al. 1997, Sheldon 2005). The biofilm can act as a shield for the bacteria, making it difficult for them to be reached and destroyed by antibiotic drugs. Two main mechanisms have been proposed to explain how bacteria in biofilms become resistant: (1) antibiotics do not reach bacteria present in the deeper layers of biofilms because of the difficulty in penetrating the exopolysaccharide gel (slime), and (2) bacteria in deeper layers may be in a metabolic state that makes them less susceptible to antibiotics (Costerton et al. 1987). Arciola et al. (2005) found that exopolysaccharide-producing bacterial strains showed a significantly higher occurrence of antibiotic resistance than those strains that did not produce exopolysaccharides. This may explain why only one-third of prosthetic joint infections caused by slime-positive organisms can be successfully treated with antibiotics, while all infections caused by slime-negative organisms can be cured by antibiotic therapy (Davenport et al. 1986).

Although bacteria in biofilms are surrounded by an exopolysaccharide matrix that can restrict the

diffusion of antibiotics, this may not be the central reason for biofilm-related antibiotic resistance. Jefferson et al. (2005) showed that the antibiotic vancomycin can fully penetrate the biofilm but the diffusion rate in a biofilm is significantly reduced as compared to in water. This suggests that whereas planktonic bacteria are quickly exposed to a high concentration of antibiotics, bacteria in the deeper layers of the biofilm are exposed to a gradually increasing antibiotic concentration. Darouiche et al. (1994) showed good penetration of biofilms by vancomycin, but that the resident bacteria were resistant. Likewise, rifampin has been found to penetrate biofilms formed by *Staphylococcus epidermidis* but fails to kill the bacteria effectively (Zheng and Stewart 2002). These studies indicate that even though the biofilm is not a physical barrier, it somehow does cause antibiotic resistance.

Based on their own results, Ashby et al. (1994) suggested that the growth rate of the bacteria in biofilms plays a role in antibiotic resistance. The bacteria in a biofilm do not grow exponentially; they are influenced by high cell densities (Fux et al. 2005) and are in a slow-growing or stationary phase (Costerton et al. 1999, Fux et al. 2005). However, not all biofilm bacteria are resistant to antibiotics; most cells die after antibiotic therapy and only a small proportion of bacteria usually survive (Ashby et al. 1994, Muli and Struthers 1998). It has been suggested that some bacterial cells in the biofilm develop a phenotype that renders them resistant to antibiotics (Cochran et al. 2000, Lewis 2005) and that this development is triggered by environmental signals. The resistant cells are called persister cells (Stewart 2002, Lewis 2005).

Biofilm bacteria may produce persister cells that neither grow nor die in the presence of antibiotics (Cogan 2006). Persister cells are largely responsible for the high levels of tolerance to antibiotics seen in biofilms (Lewis 2005), but the environmental stimuli that turn on the switch to the persister phenotype are poorly understood. Keren et al. (2004) stated that production of *Escherichia coli* persisters depends on the phase of growth, since maintaining the *E. coli* culture at early exponential phase eliminated the persister cells. Similar dynamics were observed with *Pseudomonas aeruginosa* and *S. aureus* (Keren et al. 2004). Using a mathematical model of biofilm dynamics, Roberts

and Stewart (2005) predicted that the number of persister cells increases in the biofilm despite the fact that they are unable to grow, with accumulation in regions of nutrient and oxygen depletion. In these regions, although normal cells are unable to grow, they slowly switch to the persister phenotype. Cogan (2006) suggested that expression of persister cells is controlled by the growth rate and the antibiotic concentration. Persister cells can be regarded as specialized survivor cells. After the antibiotic treatment has stopped, surviving persister cells are able to revert quickly to normal cells, thus allowing the biofilm to grow again (Roberts and Stewart 2005).

The clinical impact of an infection depends on the capacity of the infecting organisms to form a biofilm and the ability of bacterial subpopulations to switch to the dormant metabolic state known as small-colony variants (SCVs). Although it is not known whether SCVs and persister cells express exactly the same set of genes, there are many similarities between SCVs and persister cells, especially regarding how both subpopulations are formed and their reduced sensitivity to antibiotics. Bayston (2000) hypothesized that the formation of SCVs takes place when the biofilm is thick enough to serve as a barrier for oxygen and nutrients. Nutrient and oxygen limitation causes some bacteria in the lower layers of the biofilm to enter a non-growing or “dormant” state: the SCVs, in which they are less susceptible to growth-dependent antibiotic killing.

Many infections in the developed world are caused by biofilms, which has sparked renewed interest in SCVs. The clinical relevance of SCVs has been unclear for a long time. Many recent studies have shown that SCVs are largely responsible for the recalcitrance of infections caused by biofilms (von Eiff et al. 1997, 1999, Drenkard and Ausubel 2002, Seifert et al. 2003). The significance of SCVs as causative organisms in chronic and recurrent infections has been demonstrated in patients with chronic osteomyelitis (von Eiff et al. 1997) and cystic fibrosis (Haussler et al. 1999, Drenkard and Ausubel 2002, Kiristis et al. 2005). In the treatment of chronic osteomyelitis with gentamicin-loaded bone cement beads, the slow release of gentamicin from the beads into the local environment is an efficient way of selecting for

SCVs (von Eiff et al. 1997). In a study of *S. aureus* strains isolated from patients with osteomyelitis, SCVs were found in about 29% of the cases (von Eiff et al. 1997). Likewise, the occurrence of *S. aureus* SCVs is observed in patients with cystic fibrosis (CF) after long-term antibiotic treatment (Kahl et al. 2003a). Analysis of sputum from CF patients showed that more than two-thirds were chronically colonized by *S. aureus*, and half of these samples were found to contain SCVs (Kahl et al. 2003b). Also, *P. aeruginosa* appears to play a role in the CF lung and *P. aeruginosa* SCVs were isolated from one-third of NN patients with *P. aeruginosa* infected lungs (Haussler et al. 1999). Recently, implant-related infections due to SCVs have been described, involving pacemakers (Seifert et al. 2003), ventriculoperitoneal shunts (Spanu et al. 2005), and hip replacements (Sendi et al. 2006).

Characteristic features of SCVs

The phenomenon of SCVs has been reported for several genera and species of bacteria, including the genera *Staphylococcus* (Figure 2) and *Pseudomonas*, and diverse species of Enterobacteriaceae (Bayer et al. 1987, Wise 1998, Costerton et al. 1999). Most SCVs isolated from clinical specimens have been identified as *S. aureus*. SCVs share many characteristic features, but since the greatest amount of information available relates to *S. aureus*, we have concentrated on *S. aureus* SCVs in this review.

SCVs of *S. aureus* (Table) grow slowly and produce small colonies on standard media. These are




Figure 2. Sheep blood agar plates (panels A and B) and magnified sectors (panels C and D) after overnight incubation at 37°C, showing two morphotypes of clonal isolates of *Staphylococcus lugdunensis* recovered from blood culture and the infected pocket of a patient with pacemaker infection. Panels A and C show *S. lugdunensis* with the normal phenotype, characterized by colonies with yellow pigmentation and weak hemolysis. Panels B and D show small colony variants, characterized by tiny (pinpoint) non-pigmented, non-hemolytic colonies. The pictures in this figure were taken with permission from Seifert H, Oltmanns D, Becker K, Wisplinghoff H, von Eiff C. *Staphylococcus lugdunensis* pacemaker-related infection. Emerg Infect Dis 2005 Aug;11(8):1283-6. Available from <http://www.cdc.gov/ncidod/EID/vol11no08/04-1177.htm>.

10 times smaller than the usual *S. aureus* colonies (Bergoge-Berezin 2000). SCVs have the ability to revert to normal growth (Musher et al. 1977, Lewis et al. 1991) but there are no data available about the genetic events responsible for the reappearance of larger colonies. In addition, *S. aureus* SCVs are characterized as electron transport-deficient bacteria because of their auxotrophism to hemin

Table 1. Differences in features between *S. aureus* and its SCVs

	Normal colonies of <i>S. aureus</i>	Small colony variants of <i>S. aureus</i>	References
Colony size (approx.)	2 mm	0.2 mm	Bergoge-Berezin 2000, Roggenkamp et al. 1998
Coagulase production	Yes	No	Seifert et al. 2003
Hemolytic	Yes	No	Balwit et al. 1994
Pigment	Yes	No	Balwit et al. 1994, Proctor et al. 1998
Auxotrophism, hemin and/or menadion	No	Yes	Kahl et al. 2003, Proctor and Peters 1998
Sensitivity to aminoglycoside antibiotics	Sensitive	Resistant	Rusthoven et al. 1979, Proctor and Peters 1998
Intracellular survival	No	Yes	Kahl et al. 1998, Vaudaux et al. 2002, von Eiff et al. 2001

or menadione. Hemin/menadione auxotrophy is the inability of an organism to synthesize hemin or menadione, which is required for its growth. Hemin or menadione auxotrophs will therefore only be able to grow if hemin or menadione can be taken up from the environment. Consequently, these SCVs produce very small, mostly non-pigmented, and non-hemolytic colonies on normal agar plates. Moreover, they show various other features that are atypical of *S. aureus*, including reduced coagulase production and increased resistance to aminoglycosides and cell wall-active antibiotics (von Eiff et al. 1997, Proctor and Peters 1998, Proctor et al. 1998, Kahl et al. 1998, 2003a, Seifert et al. 1999, Baumert et al. 2002). Furthermore, the ability of these variants to persist intracellularly within non-professional phagocytes, cells other than macrophages and neutrophils, has been described (Kahl et al. 1998, von Eiff et al. 2001, Vaudaux et al. 2002). *S. aureus* SCVs are capable of living intracellularly and consequently survive antibiotic therapy because they produce reduced levels of α -toxin, which prevents the cells from lysing (von Eiff et al. 2000).

Failure to diagnose biofilm infections in orthopedics

Infection after joint replacement can present a diagnostic challenge, especially in late-onset infection, as the patient's pain may mimic that experienced from other common complications of the surgery. There are no preoperative tests that are consistently sensitive and specific for infection in patients who need revision surgery. Definitive diagnosis based solely on history and physical findings may prove inaccurate. The only consistent clinical finding in biofilm infections is pain at the site of the implant. However, patients with early onset of their infection typically have pain, redness, and swelling at the joint, or drainage from the wound, while patients who develop infections later in recovery complain of a gradual onset of joint pain—often without fever or other obvious signs of joint infection. There are less clinical signs and symptoms of infection in those patients. Hematological testing, radiographs and bone scans are highly variable, and all may give positive results in both aseptic loosening and infection, making these indicators of limited use. In addition, the sensitivity of preopera-

tive aspiration of the infected joint does not exceed 75% (Barrack et al. 1997). Only the sum of clinical signs and symptoms, blood tests, radiography, and a microbiological workup can provide an accurate diagnosis. Investigation of suspected infection in prosthetic joint replacements remains a difficult orthopedic problem, with important therapeutic implications. It is extremely important to be able to differentiate aseptic loosening from infection, as the treatment of these two is totally different.

Auxotrophism

Intraoperative specimens provide the most accurate samples for microbiological culture and are frequently used as the reference standard for diagnosing infected joint replacements. However, standard microbiological culture techniques are only moderately sensitive and specific in diagnosing infected arthroplasties. A very low inoculum, adherent bacteria, and the existence of SCVs may limit detection. Consequently, a significant proportion of these infections is probably never recognized (Philips and Kattapuram 1983, Tunney et al. 1998, Costerton et al. 1999, Neut et al. 2003). The incidence of infection in joint prostheses may therefore be grossly underestimated, and hypothetically it might be argued that inadequate microbial sampling by current hospital diagnostic methods is at least partially responsible for the high failure rates in revision surgery. Adequate sampling is extremely important in clinical practice—as, for example, septic joint prostheses require eradication of the infecting bacteria before implantation of a new prosthesis, whereas uninfected joint prostheses can be replaced immediately.

Although microscopic morphology and cell size, and Gram staining of SCVs may be normal (Haussler et al. 1999, Looney 2000), clinical microbiology laboratories may fail to detect them. Since these phenotypic variants have a low metabolism and grow very slowly on standard agar plates, they can easily be missed in a routine laboratory, where tissue samples are cultured for only 48 h. Colony formation by SCVs can often be detected on culture media after 48–72 h of culture during primary isolation (Proctor et al. 1995, Roggenkamp et al. 1998). Neut et al. (2003) showed that prolonging the culture period of microbiological samples from infected joint prostheses could double the detection

rate for infections, as bacteria in biofilms generally require a longer time in culture (Atkins and Bowler 1998). As *S. aureus* SCVs show generation times of up to 6 times longer than that for metabolically normal *S. aureus* (Proctor et al. 1995), cultures for detection of SCVs should be incubated for at least 6 days (Looney 2000). The addition of hemin and menadion to routine blood agar used for hospital culture increases the detection rate, as SCVs form normal-sized colonies and grow at the same speed as the parent strain on agar plates enriched with hemin and menadione (Kahl et al. 2003a). SCVs cultured from patients with persistent and relapsing infections have been shown to be auxotrophic for hemin and/or menadion (Proctor and Peters 1998). Supplementation of the auxotrophs with exogenous menadione or hemin resulted in normal growth and morphology, and increased hemolytic activity (Balwit et al. 1994). Subcultivation of SCVs showed hemin-dependent growth: formation of larger colonies (diameter 2 mm) in the presence of hemin and formation of small colonies (diameter 0.2 mm) in its absence (Roggenkamp et al. 1998).

Because of their particular growth characteristics, atypical morphological appearance, and unusual biochemical reactions (e.g. reduced toxin production), SCVs present a challenge to the clinical microbiologist, often resulting in misidentification (Proctor et al. 1995, 1998, Proctor and Peters 1998). For example, Seifert et al. (2003) described case studies in which blood cultures yielded non-pigmented and non-hemolytic staphylococci, which were initially identified as coagulase-negative staphylococci on the basis of a negative tube coagulation test and the API ID 32 Staph system. However, the morphological appearance of colonies was suggestive of SCVs of *S. aureus*, and this was confirmed by DNA amplification using the polymerase chain reaction (PCR). Likewise, using molecular methods, Spanu et al. (2005) identified *S. aureus* SCVs that were methicillin-resistant, while these had originally been identified by 3 widely used automated identification systems as being methicillin-susceptible coagulase-negative staphylococci. Thus, it is most important to take SCVs into account as a possible cause of persistent infectious diseases, particularly when no bacteria or unusual microorganisms can be found in specimens from such cases.

Reduced production of virulence factors

When there is a suspicion of an infected joint prosthesis, biochemical investigations can be performed. Erythrocyte sediment rate (ESR) and C-reactive protein (CRP) levels are important laboratory parameters in the diagnosis of postoperative infection in patients. In joint prosthesis infections caused by bacteria of high virulence, high CRP and ESR values are common (Shih et al. 1987, Sanzén and Carlsson 1989), but in low-grade infections the absence of elevated levels of these two parameters does not exclude the possibility of a biofilm infection. Most recent studies tend to favor CRP over ESR, mainly because of the fact that ESR is affected by a multitude of factors (Ng 1998). CRP levels rise early and before the onset of clinical symptoms, and decline with the resolution of infection. Cytokines, particularly IL-6, induce synthesis of CRP in the liver (Kraggsbjerg and Holmberg 1995). As part of their general reduction in metabolic activity, *S. aureus* SCVs do not produce virulence factors such as α -toxin, coagulase, or other products that are associated with stimulation of cytokine release and immune response (Bayston 2000). Limited release of cytokines at the site of an infection with SCVs does not cause elevated levels of CRP. Thus, measurement of the CRP level is not an adequate diagnostic tool when establishing that there is a postoperative infection caused by SCVs.

Failure in treatment of biofilm infections in orthopedics

Treatment of infected joint replacements is difficult, and usually requires appropriate surgical intervention combined with a prolonged course of antibiotic therapy. The choice of optimal management depends on the duration and pathogenesis of the infection, stability of the implant, antibiotic susceptibility of the pathogen, and condition of the soft tissue. To eradicate chronic prosthesis infection, most authors recommend removal of the implant (McDonald et al. 1989, Tattevin et al. 1999) and two-stage revision surgery. Prior to a successful reimplantation after infection, the infection should be fully eradicated through surgical debridement and removal of the prosthesis. Subsequently, high local levels of antibiotics can be achieved in the compromised tissue by implantation of chains of gentamicin-loaded bone cement beads, before a

second prosthesis is actually implanted. The gentamicin concentration that can be achieved in this way is much higher than with systemic administration (Walenkamp 1997). These beads are usually removed after 2 weeks and the absence of cultivable microorganisms in excised soft tissue samples by routine hospital culture is taken as a sign that the infection has been eradicated, and implantation of a new prosthesis can take place. Although the use of gentamicin-loaded beads is accepted in clinical practice, the beads themselves can act as a biomaterial surface to which subpopulations of bacteria may preferentially adhere, grow and possibly even develop antibiotic resistance (Neut et al. 2001).

The slow release of gentamicin from the beads into the local environment is an efficient way of selecting for SCVs (von Eiff et al. 1997). In routine hospital culture, such minority populations are disregarded, but their presence may have consequences in the subsequent treatment of a patient after orthopedic revision surgery. Neglecting SCVs will contribute to the occurrence of reinfections after employing gentamicin-loaded beads, and this may be one of the reasons for higher infection rates after revision surgery.

Antibiotic resistance

Bacteria persisting as SCVs within biofilms may explain the recurrent nature of biofilm infections. SCVs cause persistent and relapsing infections due to their increased resistance to antibiotics. The depressed electron transport activity seen in these auxotrophic SCVs may account for their *in vitro* resistance to a variety of antibiotics (Proctor and Peters 1998). In addition, SCVs have defective catalase activity, which may interfere with oxidative metabolism and aminoglycoside uptake (Rusthoven et al. 1979). The low content of ATP in SCVs causes inefficient transport of aminoglycosides into the cell, resulting in increased resistance to gentamicin and other aminoglycosides (Proctor and Peters 1998). The minimum inhibitory concentrations of four aminoglycoside antibiotics were found to be 8- to over 16 times higher for SCVs than for the normal large colony type (Rusthoven et al. 1979). Moreover, the slow growth of SCVs and consequently cell-wall division reduces the effectiveness of antibiotics that act at the cell wall (Looney 2000). However, SCVs are susceptible to a

range of antibiotics with other modes of action, the hydrophilic antibiotics tetracycline and erythromycin for example, and to the hydrophobic antibiotics rifampicin and chloramphenicol (Langford et al. 1989). For optimal eradication of SCVs, treatment should consist of therapy with an antibiotic that has optimal bactericidal activity against slowly growing bacteria (Vaudaux et al. 2006). Rifampin may be the most efficient antibiotic because of its excellent efficacy against stationary and adherent bacteria (Widmer et al. 1990). Although rifampin has very good bactericidal activity against slow-growing bacteria, it should be given in combination with other antibiotics because of the rapid emergence of resistance when given alone (Vaudaux et al. 2006). The combination proposed by Sendi et al. (2006), rifampin with a fluoroquinolone, has been shown to be successful when dealing with hip replacements infected with *S. aureus* SCVs.

Intracellular survival

S. aureus SCVs can survive inside non-professional phagocytes, such as endothelial cells and osteoblasts (Hudson et al. 1995, von Eiff et al. 2000). These SCVs have a dampened production of cytotoxins and this may downregulate the induction of cell lysis or apoptosis (Proctor et al. 2006). Unlike the wild type, they do not kill the cells because they produce very little α -toxin (von Eiff et al. 2000). Their reduced virulence creates a completely new niche for these bacteria inside the host cell (Proctor 1994, Proctor et al. 1995). The intracellular location may shield these SCVs from the host defenses and exposure to antibiotics (Kahl et al. 1998, Vaudaux et al. 2002, von Eiff et al. 2001), thus providing one explanation for the difficulty in clearing SCVs from host tissues. In addition, *S. aureus* SCVs can also be phagocytosed by monocytes and macrophages. They can hide within these host cells, then revert to the highly virulent rapidly growing form and lyse the host cell once the host immune response has dropped and antibiotic therapy is complete (von Eiff et al. 2000). *S. aureus* persisting as SCVs inside host cells may also be an explanation for the recurrent nature of these biofilm infections.

Conclusions

Clinical and laboratory findings lead to the con-

clusion that SCVs must be actively sought after in clinical microbiology, because they grow very slowly and can easily be missed. Particularly those samples from patients who have undergone long-term antibiotic therapy (e.g. antibiotic-loaded bone cement beads or spacers) or from individuals suffering from unusually persistent or recurrent infections should be examined meticulously for SCVs. In addition, it is most important to take SCVs into account as a possible cause of persistent infectious diseases when no bacteria or unusual microorganisms are found in materials obtained from such cases. Also, due to reduced production of virulence factors by SCVs, absence of elevated levels of CRP in patients postoperatively does not exclude the possibility of a biofilm infection. An optimal treatment of SCV-mediated infections has not been established, but these bacterial forms show increased resistance to aminoglycosides and cell-wall active antibiotics.

Contributions of authors

DN: conception and design of the study, data collection, analysis, and manuscript preparation. HvdM, SB, and HB: study design, analysis, and revision of the manuscript.

No competing interests declared.

Arciola C R, Campoccia D, Gamberini S, Donati M E, Pirini V, Visai L, Speziale P, Montanaro L. Antibiotic resistance in exopolysaccharide-forming *Staphylococcus epidermidis* clinical isolates from orthopaedic implant infections. *Biomaterials* 2005; 26: 6530-5.

Ashby M J, Neale J E, Knott S J, Critchley I A. Effect of antibiotics on non-growing planktonic cells and biofilms of *Escherichia coli*. *J Antimicrob Chemother* 1994; 33: 443-52.

Atkins B L, Bowler I C. The diagnosis of large joint sepsis. *J Hosp Infect* 1998; 40: 263-74.

Balwit J M, Van Langevelde P, Vann J M, Proctor R A. Gentamicin-resistant menadione and hemin auxotrophic *Staphylococcus aureus* persist within cultured endothelial cells. *J Infect Dis* 1994; 170: 1033-7.

Barrack R L, Jennings R W, Wolfe M W, Bertot AJ. The value of preoperative aspiration before total knee revision. *Clin Orthop* 1997; (345): 8-16.

Baumert N, Von Eiff C, Schaaff F, Peters G, Proctor R A, Sahl H G. Physiology and antibiotic susceptibility of *Staphylococcus aureus* small colony variants. *Microb Drug Resist* 2002; 8: 253-60.

Bayer A S, Norman D C, Kim K S. Characterization of impermeability variants of *Pseudomonas aeruginosa* isolated during unsuccessful therapy of experimental endocarditis. *Antimicrob Agents Chemother* 1987; 31: 70-5.

Bayston R. Biofilms and prosthetic devices. In: Community structure and co-operation in biofilms (eds. Allison D G, Gilbert P, Lappin-Scott H M, Wilson M). Cambridge university press 2000: 295-308.

Bergoge-Berezin E. Resistance and new antibiotic strategies. The problem with staphylococcus. *Presse Med* 2000; 29: 2018-21.

Bos R, Van der Mei H C, Busscher H J. Physico-chemistry of initial microbial adhesive interactions--its mechanisms and methods for study. *FEMS Microbiol Rev* 1999; 23: 179-230.

Cochran W L, Suh S J, McFeters G A, Stewart P S. Role of RpoS and AlgT in *Pseudomonas aeruginosa* biofilm resistance to hydrogen peroxide and monochloramine. *J Appl Microbiol* 2000; 88: 546-53.

Cogan N G. Effects of persister formation on bacterial response to dosing. *J Theor Biol* 2006; 238: 694-703.

Costerton J W, Cheng K J, Geesey G G, Ladd T I, Nickel J C, Dasgupta M, Marrie T J. Bacterial biofilms in nature and disease. *Annu Rev Microbiol* 1987; 41: 435-64.

Costerton J W, Stewart P S, Greenberg E P. Bacterial biofilms: a common cause of persistent infections. *Science* 1999; 284: 1318-22.

Darouiche R O, Dhir A, Miller A J, Landon G C, Raad II, Musher DM. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. *J Infect Dis* 1994; 170: 720-3.

Davenport D S, Massanari R M, Pfaller M A, Bale M J, Streed S A, Hierholzer W J Jr. Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. *J Infect Dis* 1986; 153: 332-9.

Drenkard E, Ausubel F M. *Pseudomonas* biofilm formation and antibiotic resistance are linked to phenotypic variation. *Nature* 2002; 416: 740-3.

Fux C A, Costerton J W, Stewart P S, Stoodley P. Survival strategies of infectious biofilms. *Trends Microbiol* 2005; 13: 34-40.

Gracia E, Fernandez A, Conchello P, Lacleriga A, Paniagua L, Seral F, Amorena B. Adherence of *Staphylococcus aureus* slime-producing strain variants to biomaterials used in orthopaedic surgery. *Int Orthop* 1997; 21: 46-51.

Gristina A G. Biomaterial-centered infection; microbial adhesion versus tissue integration. *Science* 1987; 237: 1588-95.

Gristina A G, Costerton J W. Bacterial adherence to biomaterials and tissue: The significance of its role in clinical sepsis. *J Bone Joint Surg (Am)* 1985; 67: 264-73.

Haussler S, Tummler B, Weissbrodt H, Rohde M, Steinmetz I. Small-colony variants of *Pseudomonas aeruginosa* in cystic fibrosis. *Clin Infect Dis* 1999; 29: 621-5.

Hudson M C, Ramp W K, Nicholson N C, Williams A S, Nousiainen M T. Internalization of *Staphylococcus aureus* by cultured osteoblasts. *Microb Pathog* 1995; 19: 409-19.

- Jefferson K K, Goldmann D A, Pier G B. Use of confocal microscopy to analyze the rate of vancomycin penetration through *Staphylococcus aureus* biofilms. *Antimicrob Agents Chemother* 2005; 49: 2467-73.
- Josefsson G, Kolmert L. Prophylaxis with systematic antibiotics versus gentamicin bone cement in total hip arthroplasty. A ten-year survey of 1,688 hips. *Clin Orthop* 1993; (292): 210-4.
- Kahl B, Herrmann M, Everding A S, Koch H G, Becker K, Harms E, Proctor R A, Peters G. Persistent infection with small colony variant strains of *Staphylococcus aureus* in patients with cystic fibrosis. *J Infect Dis* 1998; 177: 1023-9.
- Kahl B C, Belling G, Reichelt R, Herrmann M, Proctor R A, Peters G. Thymidine-dependent small-colony variants of *Staphylococcus aureus* exhibit gross morphological and ultrastructural changes consistent with impaired cell separation. *J Clin Microbiol* 2003a; 41: 410-3.
- Kahl B C, Duebbers A, Lubritz G, Haerberle J, Koch H G, Ritzerfeld B, Reilly M, Harms E, Proctor R A, Herrmann M, Peters G. Population dynamics of persistent *Staphylococcus aureus* isolated from the airways of cystic fibrosis patients during a 6-year prospective study. *J Clin Microbiol* 2003b; 41: 4424-7.
- Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. *FEMS Microbiol Lett* 2004; 230: 13-8.
- Kirisits M J, Prost L, Starkey M, Parsek M R. Characterization of colony morphology variants isolated from *Pseudomonas aeruginosa* biofilms. *Appl Environ Microbiol* 2005; 71: 4809-21.
- Kraggsbjerg P, Holmberg H. Serum concentrations of interleukin-6, tumour necrosis factor- α , and C-reactive protein in patients undergoing major operations. *Eur J Surg* 1995; 161: 17-22.
- Kurtz S, Mowat F, Ong K, Chan N, Lau E, Halpern M. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. *J Bone Joint Surg (Am)* 2005; 87: 1487-97.
- Langford P R, Anwar H, Gonda I, Brown M R. Outer membrane proteins of gentamicin induced small colony variants of *Pseudomonas aeruginosa*. *FEMS Microbiol Lett* 1989; 61: 33-6.
- Lewis K. Persister cells and the riddle of biofilm survival. *Biochemistry (Mosc)* 2005; 70: 267-74.
- Lewis L A, Li K B, Gousse A, Pereira F, Pacheco N, Pierre S, Kodaman P, Lawson S. Genetic and molecular analysis of spontaneous respiratory deficient (res) mutants of *Escherichia coli* K-12. *Microbiol Immunol* 1991; 35: 289-301.
- Lidwell O M, Lowbury E J, Whyte W, Blowers R, Stanley S J, Lowe D. Airborne contamination of wounds in joint replacement operations: the relationship to sepsis rates. *J Hosp Infect* 1983; 4: 111-31.
- Looney W J. Small-colony variants of *Staphylococcus aureus*. *Br J Biomed Sci* 2000; 57: 317-22.
- Mah T F, Pitts B, Pellock B, Walker G C, Stewart P S, O'Toole G A. A genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature* 2003; 426: 306-10.
- McDonald D J, Fitzgerald R H Jr, Ilstrup D M. Two-stage reconstruction of a total hip arthroplasty because of infection. *J Bone Joint Surg (Am)* 1989; 71: 828-34.
- Muli F W, Struthers J K. The growth of *Gardnerella vaginalis* and *Lactobacillus acidophilus* in Sorbarod biofilms. *J Med Microbiol* 1998; 47: 401-5.
- Musher D M, Baughn R E, Templeton G B, Minuth J N. Emergence of variant forms of *Staphylococcus aureus* after exposure to gentamicin and infectivity of the variants in experimental animals. *J Infect Dis* 1977; 136: 360-9.
- Neut D, Van de Belt H, Stokroos I, Van Horn J R, Van der Mei H C, Busscher H J. Biomaterials-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. *J Antimicrob Chemo* 2001; 47: 885-91.
- Neut D, Van Horn J R, Van Kooten T G, Van der Mei H C, Busscher H J. Detection of biomaterial-associated infections in orthopaedic joint implants. *Clin Orthop* 2003; (413): 261-8.
- Ng T. Erythrocyte sedimentation rate, plasma viscosity and C-reactive protein in clinical practice. *Br J Hosp Med* 1998; 58: 521-3.
- Philips J E, Crane T P. The incidence of deep prosthetic infections. *J Bone Joint Surg (Br)* 2006; 88 (7): 943-8.
- Philips W C, Kattapuram S V. Efficacy of preoperative hip aspiration performed in the radiology department. *Clin Orthop* 1983; (179): 141-6.
- Pittet D, Duce G. Infectious risk factors related to operating rooms. *Infect Control Hosp Epidemiol* 1994; 15: 456-62.
- Proctor R A. Microbial pathogenic factors: small colony variants. In: *Infections associated with indwelling medical devices* (eds. Bisno A L, Waldvogel F A). Washington DC: American Society for Microbiology 1994: 79-90.
- Proctor R A, Peters G. Small colony variants in staphylococcal infections: diagnostic and therapeutic implications. *Clin Infect Dis* 1998; 27: 419-23.
- Proctor R A, Van Langevelde P, Kristjansson M, Maslow J N, Arbeit R D. Persistent and relapsing infections associated with small-colony variants of *Staphylococcus aureus*. *Clin Infect Dis* 1995; 20: 95-102.
- Proctor R A, Kahl B, von Eiff C, Vaudaux P E, Lew D P, Peters G. Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. *Clin Infect Dis* 1998; 27: S68-S74.
- Proctor R A, von Eiff C, Kahl B C, Becker K, McNamara P, Herrmann M, Peters G. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. *Nat Rev Microbiol* 2006; 4: 295-305.
- Roberts M E, Stewart P S. Modelling protection from antimicrobial agents in biofilms through the formation of persister cells. *Microbiology* 2005; 151: 75-80.
- Roggenkamp A, Sing A, Hornef M, Brunner U, Autenrieth I B, Heesemann J. Chronic prosthetic hip infection caused by a small-colony variant of *Escherichia coli*. *J Clin Microb* 1998; 36: 2530-4.
- Rusthoven J J, Davies T A, Lerner S A. Clinical isolation and characterization of aminoglycoside-resistant small colony variants of *Enterobacter aerogenes*. *Am J Med* 1979; 67: 702-6.

- Sanzén L, Carlsson A S. The diagnostic value of C-reactive protein in infected total hip arthroplasties. *J Bone Joint Surg (Br)* 1989; 71: 638-41.
- Seifert H, Von Eiff C, Fätkenheuer G. Fatal case due to methicillin-resistant *Staphylococcus aureus* small colony variants in an AIDS patient. *Emerg Infect Dis* 1999; 5: 450-3.
- Seifert H, Wisplinghoff H, Schnabel P, von Eiff C. Small colony variants of *Staphylococcus aureus* and pacemaker-related infection. *Emerg Infect Dis* 2003; 9: 1316-8.
- Sendi P, Rohrbach M, Graber P, Frei R, Ochsner P E, Zimmerli W. *Staphylococcus aureus* small colony variants in prosthetic joint infection. *Clin Infect Dis* 2006; 43: 961-7.
- Sheldon A T Jr. Antibiotic resistance: a survival strategy. *Clin Lab Sci* 2005; 18: 170-80.
- Shih L Y, Wu J J, Yang D J. Erythrocyte sedimentation rate and C-reactive protein values in patients with total hip arthroplasty. *Clin Orthop* 1987; 225: 238-46.
- Spanu T, Romano L, D'Inzeo T, Masucci L, Albanese A, Papacci F, Marchese E, Sanguinetti M, Fadda G. Recurrent ventriculoperitoneal shunt infection caused by small-colony variants of *Staphylococcus aureus*. *Clin Infect Dis* 2005; 41: 48-52.
- Stewart P S. Mechanisms of antibiotic resistance in bacterial biofilms. *Int J Med Microbiol* 2002; 292: 107-13.
- Tattevin P, Cremieux A C, Pottier P, Hutten D, Carbon C. Prosthetic joint infection: when can prosthesis salvage be considered? *Clin Infect Dis* 1999; 29: 292-5.
- Tunney M M, Patrick S, Gorman S P, Nixon J R, Anderson N, Davis R I, Hanna D, Ramage G. Improved detection of infection in hip replacements. A currently underestimated problem. *J Bone Joint Surg (Br)* 1998; 80: 568-72.
- Vaudaux P, Francois P, Bisognano C, Kelley W L, Lew D P, Schrenzel J, Proctor R A, McNamara P J, Peters G, Von Eiff C. Increased expression of clumping factor and fibronectin-binding proteins by hemB mutants of *Staphylococcus aureus* expressing small colony variant phenotypes. *Infect Immun* 2002; 70: 5428-37.
- Vaudaux P, Kelley W L, Lew D P. *Staphylococcus aureus* small colony variants: difficult to diagnose and difficult to treat. *Clin Infect Dis* 2006; 43: 968-70.
- Von Eiff C, Bettin D, Proctor R A, Rolauffs B, Lindner N, Winkelmann W, Peters G. Recovery of small colony variants of *Staphylococcus aureus* following gentamicin bead placement for osteomyelitis. *Clin Infect Dis* 1997; 25: 1250-1.
- Von Eiff C, Vaudaux P, Kahl B C, Lew D, Emler S, Schmidt A, Peters G, Proctor R A. Bloodstream infections caused by small-colony variants of coagulase-negative staphylococci following pacemaker implantation. *Clin Infect Dis* 1999; 29: 932-4.
- Von Eiff C, Proctor R A, Peters G. *Staphylococcus aureus* small colony variants: formation and clinical impact. *Int J Clin Pract* 2000; 115: S44-9.
- Von Eiff C, Becker K, Metzke D, Lubritz G, Hockmann J, Schwarz T, Peters G. Intracellular persistence of *Staphylococcus aureus* small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Darier's disease. *Clin Infect Dis* 2001; 32: 1643-7.
- Walenkamp G H I M. Chronic osteomyelitis. *Acta Orthop Scand* 1997; 68: 497-506.
- Widmer A F. New developments in diagnosis and treatment of infection in orthopedic implants. *Clin Infect Dis* 2001; 33: S94-106.
- Widmer A F, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. *J Infect Dis* 1990; 162: 96-102.
- Wise R I. Small colonies (G variants) of staphylococci: isolation from cultures and infection. *Ann NY Acad Sci* 1998; 65: 169-74.
- Zheng Z, Stewart P S. Penetration of rifampin through *Staphylococcus epidermidis* biofilms. *Antimicrob Agents Chemother* 2002; 46: 900-3.